Group items tagged

This Pharmacy First Common Ailments service will help patients seek treatment for seven common conditions directly from a pharmacy without the need for a GP appointment or prescription. Launching on 31 January next year although it is subject to IT being ready, the service will cover ailments including "sinusitis, sore throat, earache, infected insect bites, impetigo, shingles, and uncomplicated urinary tract infections (UTIs)" in women. People with symptoms of the above seven conditions will be supplied with a prescription-only treatment under a Patient Group Direction (PGD). Patients seeking assistance at the pharmacy, whether walk-in or referred by NHS 111, GPs, or other sources, can receive consultations. The new service includes self-referring patients plus referrals, and the Community Pharmacist Consultation Service (CPCS) will also be a part of it.

The much-awaited Pharmacy First service has been launched in England, enabling patients to get treatment for seven common conditions from their community pharmacists without needing to see a GP. According to NHS England, a total of 10,265 community pharmacies, which is equivalent to more than nine in ten community pharmacies in the country, will be offering the ground-breaking initiative. The new scheme allows highly trained pharmacists to give advice and prescription-only medicines for minor ailments including sinusitis, sore throat, earache, infected insect bite, impetigo, shingles, and uncomplicated urinary tract infections in women (under the age of 65). With this major expansion of pharmacy services, the NHS is aiming to free up 10 million GP appointments a year while giving the public more choice in where and how they access care.

The NHS plans to train hundreds of pharmacy staff, expanding their ability to provide advanced clinical services and assume wider roles in dispensing medicines. With a targeted launch in September, up to 840 pharmacy technicians can join in the training programme. The online modules will cover consultation skills, therapeutics, clinical decision-making, assessment skills, and service improvement. "Community pharmacies are pivotal in local communities, and this novel training scheme empowers them to extend their service offerings to a wider patient base," said Health Minister Neil O'Brien. "Through our investment in the workforce, we're bolstering the implementation of the Pharmacy First initiative with £645 million, ensuring patients have access to expert assistance for various common ailments, including urinary tract infections and earaches." NHS said the training will offer flexibility to align with the working schedules and prior experience of community pharmacy technicians. It will combine independent online e-course study, educational supervision, and clinical skills training. Facilitated workshops will concentrate on enhancing clinical assessment skills and applying knowledge and skills through case studies, practice activities, and group discussions.

The International Pharmaceutical Federation (FIP) launched a report on pharmacy-led common ailment schemes. The data was collected from 24 countries, including case studies from nine countries. It highlighted the growing demand for care models for ageing populations and the increase in chronic non-communicable diseases. Pharmacists had been managing the stress, including prescribing authority and provision of medicinal treatments. Paul Sinclair AM, Global President of FIP, said, "I believe this report is both a foundation and a catalyst - a foundation on which FIP and our member organizations could base initial strategies and a catalyst to drive us to seek even more diverse and comprehensive insights in the future.

To support NHS, clear the backlog created by the Covid-19 pandemic and help community pharmacies support more people, the Welsh government has announced an allocation of further £12.5 million funding. Of the total amount, £10mn will be distributed across the 22 local authorities to buy equipment to help people to live independently in their own homes post hospital stay. The remainder, £2.5mn, will be used to support community pharmacists and patients to improve access to treatment and advice for a range of common ailments. The move is aimed at alleviating waiting times and reducing winter pressures on the NHS. Commenting on the announcement, Elen Jones, Royal Pharmaceutical Society director for Wales said: "We are delighted that the Welsh government continue to recognise the value of pharmacists in patient care and we welcome this additional investment and support for Community Pharmacy teams across Wales.

Brits are increasing relying on over-the-counter (OTC) medicines to prevent or treat common ailments, as the 'care at home trend' has become prominent amongst UK households following the COVID-19 pandemic. Almost three-quarters of Brits (71 per cent) now choose to treat minor ailments at home rather than visit their GP or pharmacist, according to new research. The self-care message promoted by the government and NHS during the pandemic has led to a new generation of consumers who continue to take control of their own health and treat minor ailments themselves. Additionally, the research, commissioned by Lanes Health, revealed that public awareness about preventative treatment has increased, with 70 per cent of Brits claiming that they do their best to prevent the spread of common illnesses since the pandemic.

Royal Pharmaceutical Society in England and the Royal College of General Practitioners have published recommendations for the roll-out and success of the GP Community Pharmacist Consultation Service (GP CPCS). These recommendations follow a workshop with stakeholders from pharmacy, general practice and representative bodies, examining ways to maximise the potential of the service and meet growing demand on the health service. The workshop report made five recommendations: The NHS England and Improvement should provide additional investment in local system support and resources to drive the CPCS implementation and uptake between general practice and community pharmacy. National representative bodies should work with NHS E&I to develop national and local engagement and streamline communication plans for CPCS referral pathway. Focus on expanding the role of community pharmacists in the management of minor illness. Evaluation of CPCS service and its impacts on general practice workload, patient outcomes and health inequalities.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the Scottish Medicines Consortium (SMC) has approved Ponvory (ponesimod) for treating adults with relapsing-remitting multiple sclerosis (RRMS) within NHS Scotland. Ponesimod offers an additional treatment choice for the ailment, which affects over 15,000 people in Scotland. Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system in which immune cells attack myelin, causing inflammation. The common symptoms of this disease include fatigue, balance and walking problems, numbness or tingling, dizziness and vertigo. Amanda Cunnington, director of Health Economics, Market Access, Reimbursement, Government Affairs & Patient Engagement, Janssen-Cilag Limited said: "This decision further supports our commitment to ensuring patients living with this condition have access to new treatment options to help address some of the life-long and life-limiting symptoms of MS.

Proprietary Association of Great Britain, PAGB - which represents manufacturers of branded over-the-counter (OTC) medicines, self-care medical devices and food supplements - on Tuesday (12 December) celebrated 40 years of reclassification of medicines. Expanding self-care for common ailments and minor injuries will not only help ease pressure on primary care services, but also provides significant potential savings for the NHS, the consumer healthcare association highlighted during the event. Nurofen (ibuprofen) and Imodium (loperamide) were the first medicines to go through Medicines and Healthcare products Regulatory Agency (MHRA)'s switch process in 1983 to make them available over the counter - OTC. Other reclassified medicines which were once available on prescription only include Voltarol (diclofenac dimethylammonium), Canesten (clotrimazole), Nexium (esomeprazole), Nicorette, Nicotinell and Niquitin (nicotine replacement therapies), Regaine (minoxidil), Viagra Connect (sildenafil), Cialis Together (tadalafil) for erectile dysfunction and Gina (estradiol hemihydrate) for the treatment of postmenopausal symptoms such as vaginal dryness.

Following centuries of stigma, the importance of mental wellness is finally matching that of physical healthcare. Conditions such as depression have become common topics in the media, particularly in the last few years as celebrities and experts warned against the pressures of social media. The bouts of isolation connected with the Covid-19 pandemic exacerbated the issue, with the British Medical Association declaring a UK mental health crisis at the end of 2022. This media attention has led to acknowledgement of the realities of mental health problems from the government and medical sector, and a recognition that these need to be approached differently to physical ailments when it comes to providing treatment. If you are motivated to be involved in this rapidly changing industry, consider these rewarding business ideas for developing a career in mental health. Become a counsellor Counselling is a broad term, but essentially it is the practice of having impartial conversation with patients about their life experiences with a view to overcoming emotional obstacles and trauma. Training can take three to five years depending on whether you are getting a degree or diploma, and there are many opportunities to specialise both during and after your education. Psychotherapy is a similar field, but this is a more academically focused course that tends to be concerned with long-term or particularly complex mental health issues. You will need a post-graduate qualification and several years of training to become certified.